Two Randomized Trials of Canakinumab in Systemic Juvenile Idiopathic Arthritis

Ruperto, Nicolino; I. Brunner, Hermine; Quartier, Pierre; Constantin, Tamás; Wulffraat, Nico; Horneff, Gerd; Brik, Riva; McCann, Liza; Kasapçopur, Özgür; Rutkowska‐Sak, Lidia; Schneider, Rayfel; Berkun, Yackov; Calvo, Inmaculada; Ergüven, Müferet; Goffin, Laurence; Hofer, Michaël; Kallinich, Tilmann; Knupp Feitosa de Oliveira, Sheila; Uziel, Yosef; Viola, Stefania; Nistala, Kiran; Wouters, Carine; Cimaz, Rolando; Ferrandiz, M; Flatø, Berit; Luz Gámir Gámir, María; Koné‐Paut, Isabelle; A. Grom, Alexei; Magnusson, Bo; Özen, Seza; Sztajnbok, Flávio; Lheritier, K.; Abrams, Kenneth; Kim, Dennis; Martini, Alberto; J. Lovell, Daniel

doi:10.1056/nejmoa1205099

Public

Two Randomized Trials of Canakinumab in Systemic Juvenile Idiopathic Arthritis

Published in New England Journal of Medicine • Dec 19, 2012

Authors:

Nicolino Ruperto

Hermine I. Brunner

Pierre Quartier

Abstract

BACKGROUND: Interleukin-1 is pivotal in the pathogenesis of systemic juvenile idiopathic arthritis (JIA). We assessed the efficacy and safety of canakinumab, a selective, fully human, anti-interleukin-1β monoclonal antibody, in two trials. METHODS: In trial 1, we randomly assigned patients, 2 to 19 ...

Subject

Canakinumab

Medicine

Arthritis

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!